Fusion Peptide Derivative for Brain Barrier Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Peptides administered intranasally face challenges in crossing the blood-brain barrier and are prone to enzymatic decomposition, limiting their effectiveness and duration of action.
Innovation Solution
A centrally-acting peptide derivative is developed by combining a centrally-acting peptide sequence with a cell-penetrating sequence and an endosomal-escape sequence, enhancing its ability to migrate to the central nervous system and resist enzymatic degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If a peptide is administered intranasally, then the administration is less invasive and can deliver peptide to the central nervous system, but the peptide does not easily pass the blood-brain barrier and the effect is lost within a short period due to enzymatic decomposition
Solution Approach 1:
The patent applies composite materials by fusing the centrally-acting peptide with a cell-penetrating peptide sequence to create a hybrid peptide derivative. This composite structure combines the pharmacological activity of the centrally-acting peptide with the blood-brain barrier crossing capability of the cell-penetrating peptide, enabling efficient brain delivery while maintaining the therapeutic effect
Solution Approach 2:
The cell-penetrating peptide sequence acts as an intermediary that facilitates the transport of the centrally-acting peptide across the blood-brain barrier. This intermediary component enables the peptide to traverse the barrier without direct interaction between the centrally-acting peptide and the barrier, solving the delivery efficiency problem
2Ease of operation
If a peptide is administered intranasally, then the administration is less invasive, but the peptide is prone to enzymatic decomposition in a biological body
Solution Approach 1:
The patent uses composite materials by creating a fusion peptide that combines the centrally-acting peptide with a cell-penetrating peptide sequence. This composite structure provides enhanced stability by protecting the centrally-acting peptide from enzymatic decomposition while maintaining its pharmacological activity
Solution Approach 2:
The cell-penetrating peptide sequence serves as a protective layer that shields the centrally-acting peptide from enzymatic degradation in the biological body. This beforehand cushioning effect prevents the peptide from being decomposed before it can reach its target in the central nervous system
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A centrally-acting peptide derivative, including a centrally-acting portion, a cell-penetrating sequence portion, and an endosomal-escape portion.